A possible mechanism behind the advantageous “escape” from neutralizing antibodies can be different pharmacokinetics of viral vectors as compared with neutralizing antibodies: Viral vectors can use an active form of transport through cell surface receptors to enhance tumor penetration, whereas antibodies rely on passive diffusion from blood to tumors. Here, CD177 is linked to neoplasm.